RecruitingNCT06208007

Arterial Stiffening as a Predictor for Diastolic Cardiac Dysfunction and HFpEF

Sponsor

University Medical Center Goettingen

Enrollment

150 participants

Start Date

Feb 23, 2024

Study Type

OBSERVATIONAL

Conditions

Cardiovascular Morbidity Heart Failure With Preserved Ejection Fraction

Summary

Patients at risk for developing heart failure with preserved ejection fraction (HFpEF) will undergo a structured clinical assessment, transthoracic echocardiography and pulse-wave analysis to investigate the association of arterial stiffening and the development of cardiac diastolic dysfuntion and HFpEF.

Eligibility

Min Age: 18 Years

Inclusion Criteria9

One or more of the following criteria:
Age \> 60 years
Arterial hypertension (RR systolic ≥ 140 mmHg or diastolic ≥ 90 mmHg or ≥ 2 antihypertensive drugs)
Diabetes mellitus Type I or II
Atrial fibrillation
Chronic kidney disease (GFR \< 60 ml/min/1,73 m2 or urine albumin ≥ 30mg/24h or ACR ≥ 30 mg/g)
BMI ≥ 30 kg/m2
NYHA ≥ II
E/e' \> 8

Exclusion Criteria8

Left ventricular ejection fraction \< 50 %
Significant valve disease (Grade III or higher)
History of interventional or surgical valve repair
Regional wall motion abnormalities
Respiratory diseases as a known cause for dyspnea
Atrial flutter or fibrillation during examination
Hypertrophic/restrictive/arrhythmogenic/dilatative cardiomyopathies including cardiac amyloidosis or sarcoidosis and toxic cardiomyopathy
History of heart transplantation